Pilot study: Dystrophic pathways in human hair follicles after chemotherapy

Completed

• Conditions: alopecia; Hair loss; 10006291

• Registration Number: NL-OMON40394
• Lead Sponsor: Medisch Centrum Alkmaar

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

- Female patients with breast cancer
- Age 18 years or more
- Written informed consent
- Indication for at leaust one cycle of intravenous administered Docetaxel-Adriamycin-Cyclofosfamide (TAC), Fluorouracil-Epirubicin-Cyclophosphamide (FEC) or Adriamycin-Cyclophosphamide (AC).

Exclusion Criteria

- Use of scalp cooling

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Expression of damage-response pathways </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>NA</p><br>